The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuberculosis Infection
NCT ID: NCT01685905
Last Updated: 2012-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2000 participants
OBSERVATIONAL
2012-04-30
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. to compare the positivity of tuberculin skin test(TST) and QuantiFERON-TB Gold (QFT-G), and determine the level of agreement between two tests in patients with rheumatic diseases
2. to evaluate the difference in the occurrence of active TB in patients who receive both QFT-G and TST compared with those who receive only TST for detecting of Latent tuberculosis infection(LTBI) who are candidates of TNF inhibitors.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. The positive rates of QFT-G and TST as a screening test for LTBI
* The positive rates of QFT-G and TST will be analyzed
* Additional analysis will be performed according to the type of disease
2. The agreement between QFT-G and TST as a screening test for LTBI
* The agreement between QFT-G and TST will be analyzed for patients with rheumatic diseases who examined both QFT-G and TST
* Additional analysis will be performed according to the type of disease
3. The correlation of the occurrence of active TB and two tests (QFT-G and TST)
* The analysis of the correlation of the occurrence of active TB and two tests will be conducted for patients who have experienced anti-TNF agents
3-1. The occurrence of active TB in accordance with results of TST
3-2. The occurrence of active TB in accordance with results of QFT-G
3-3. The difference in the occurrence of active TB in patients performed both QFT-G and TST compared with those performed only TST for detecting of LTBI who are candidates of TNF inhibitors (pilot study).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Hanyang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sang-Cheol Bae
Professor, MD, PhD, MPH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sang-cheol Bae, director
Role: PRINCIPAL_INVESTIGATOR
Hanyang University Hospital for Rheumatic Disease
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hanyang University Hospital for rheumatic disease
Seoul, Sung-dong Gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sang-cheol Bae, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TST_IGRA
Identifier Type: -
Identifier Source: org_study_id